ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Jincheng Han

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7751-6158; OpenAlex author ID A5083564990. Sources: OpenAlex.

Their work

Papers: 3 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 10

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 3

Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model. First author DOI 10.1158/2159-8290.cd-24-0489 ↗
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer. Co-author DOI 10.1038/s43018-022-00500-z ↗
Single-cell RNA sequencing in pancreatic cancer. Co-author DOI 10.1038/s41575-021-00471-z ↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Ronald Anthony Depinho · 3 shared papers, 2021–2025 · strength 0.60
Anirban Maitra · 2 shared papers, 2021–2023 · strength 0.35
- Paper Single-cell RNA sequencing in pancreatic cancer. DOI 10.1038/s41575-021-00471-z ↗
- Paper Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable respo… DOI 10.1038/s43018-022-00500-z ↗
Yonghong Liu · 1 shared paper, 2025 · strength 0.25
- Paper Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model. DOI 10.1158/2159-8290.cd-24-0489 ↗
Huamin Wang · 1 shared paper, 2023 · strength 0.13
- Paper Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable respo… DOI 10.1038/s43018-022-00500-z ↗
Aislyn P. Schalck · 1 shared paper, 2023 · strength 0.13
- Paper Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable respo… DOI 10.1038/s43018-022-00500-z ↗
Pat Gulhati · 1 shared paper, 2023 · strength 0.13
- Paper Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable respo… DOI 10.1038/s43018-022-00500-z ↗
Haoqiang Ying · 1 shared paper, 2023 · strength 0.13
- Paper Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable respo… DOI 10.1038/s43018-022-00500-z ↗
Pingping Hou · 1 shared paper, 2023 · strength 0.13
- Paper Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable respo… DOI 10.1038/s43018-022-00500-z ↗
Michael P. Kim · 1 shared paper, 2023 · strength 0.13
- Paper Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable respo… DOI 10.1038/s43018-022-00500-z ↗
Prasenjit Dey · 1 shared paper, 2023 · strength 0.13
- Paper Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable respo… DOI 10.1038/s43018-022-00500-z ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.